Short answer
Teva Pharmaceutical Industries Ltd (TEVA) filed an 8-K current report with the SEC on September 3, 2026 reporting Item 3.03 (Material Modification to Rights of Security Holders). ADS program termination expected at market open September 14, 2026.
Teva Pharmaceutical Industries Ltd 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.03 · Material Modification to Rights of Security Holders
- ADS program termination expected at market open September 14, 2026
- Mandatory exchange: each ADS converts into one NYSE-listed ordinary share
- Rights structure shifts from ADS ownership to direct ordinary-share ownership
- Amendment No. 1 updates the deposit agreement and ADR to facilitate the conversion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Teva Pharmaceutical Industries Ltd 8-K filings
Get the next TEVA 8-K as it lands
Follow TEVA for push alerts, or ask the research agent what this filing means.